Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
687 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02935634 | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer(FRACTION-GC) | completed | Phase 2 | 190 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 9, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 |
| clinicaltrials |
| NCT04519151 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | recruiting | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04631211 | Thrombosomes® in Bleeding Thrombocytopenic Patients Study | terminated | Phase 2 | 21 | Cellphire Therapeutics, Inc.INDUSTRY | 3 | May 25, 2023 | clinicaltrials |
| NCT02511223 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer(10) | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT03386721 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 2 | 256 | Hoffmann-La RocheINDUSTRY | 15 | Feb 21, 2023 | clinicaltrials |
| NCT04733833 | A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 | completed | Phase 2 | 5 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML(SOPRA) | completed | Phase 2 | 317 | Karyopharm Therapeutics IncINDUSTRY | 11 | Jan 26, 2023 | clinicaltrials |
| NCT03166397 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | unknown | Phase 2 | 30 | Sheba Medical CenterOTHER_GOV | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02606461 | Selinexor in Advanced Liposarcoma(SEAL) | completed | Phase 2 / Phase 3 | 342 | Karyopharm Therapeutics IncINDUSTRY | 10 | Jan 23, 2023 | clinicaltrials |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | completed | Phase 2 | 122 | Millennium Pharmaceuticals, Inc.INDUSTRY | 18 | Dec 20, 2022 | clinicaltrials |
| NCT02996110 | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma(FRACTION-RCC) | completed | Phase 2 | 182 | Bristol-Myers SquibbINDUSTRY | 6 | Dec 19, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 120 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Sep 19, 2022 | clinicaltrials |
| NCT02639546 | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors(iMATRIXcobi) | completed | Phase 1 / Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03414047 | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 19, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies(CheckMate 908) | completed | Phase 2 | 166 | Bristol-Myers SquibbINDUSTRY | 15 | Aug 9, 2022 | clinicaltrials |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | terminated | Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma(UNITY-NHL) | terminated | Phase 2 / Phase 3 | 710 | TG Therapeutics, Inc.INDUSTRY | 9 | Jul 21, 2022 | clinicaltrials |
| NCT01062399 | Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme(RTOG 0913) | completed | Phase 1 / Phase 2 | 279 | Radiation Therapy Oncology GroupNETWORK | 3 | Jun 9, 2022 | clinicaltrials |
| NCT05385263 | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion | unknown | Phase 2 | 20 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT02623010 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02659020 | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma(ANNOUNCE 2) | completed | Phase 1 / Phase 2 | 310 | Eli Lilly and CompanyINDUSTRY | 10 | May 9, 2022 | clinicaltrials |
| NCT01724866 | Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer | completed | Phase 2 | 148 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Apr 15, 2022 | clinicaltrials |
| NCT05286164 | Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | unknown | Phase 2 | 30 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients(EURO-DIGNITY) | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 3 | Apr 7, 2022 | clinicaltrials |
| NCT03966742 | Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis | completed | Phase 2 | 8 | Rabin Medical CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT04640246 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | unknown | Phase 1 / Phase 2 | 60 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT04065789 | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients(KyDaR) | completed | Phase 2 | 41 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02737475 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 166 | Bristol-Myers SquibbINDUSTRY | 6 | Jan 25, 2022 | clinicaltrials |
| NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | completed | Phase 2 | 233 | Incyte CorporationINDUSTRY | 14 | Jan 24, 2022 | clinicaltrials |
| NCT03647488 | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | completed | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 24, 2022 | clinicaltrials |
| NCT01981850 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | completed | Phase 2 | 125 | Hoffmann-La RocheINDUSTRY | 8 | Jan 5, 2022 | clinicaltrials |
| NCT02857426 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)(CheckMate 647) | completed | Phase 2 | 66 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 23, 2021 | clinicaltrials |
| NCT01677741 | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | completed | Phase 1 / Phase 2 | 85 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 24, 2021 | clinicaltrials |
| NCT02824952 | Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC | unknown | Phase 2 | 40 | Shaare Zedek Medical CenterOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT00865969 | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma(PTCL) | completed | Phase 2 | 129 | Spectrum Pharmaceuticals, IncINDUSTRY | 17 | Oct 29, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tiziana Life Sciences LTDINDUSTRY | 3 | Oct 12, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials